NOV-002, Doxorubicin, Cyclophosphamide, and Docetaxel in Women With Newly Diagnosed Stage II or IIIC Breast Cancer
Status:
Completed
Trial end date:
2011-04-01
Target enrollment:
Participant gender:
Summary
RATIONALE: Oxidized glutathione (NOV-002) may stimulate the immune system in different ways
and stop tumor cells from growing. Drugs used in chemotherapy, such as doxorubicin,
cyclophosphamide, and docetaxel, work in different ways to stop the growth of tumor cells,
either by killing the cells or by stopping them from dividing. Giving more than one drug
(combination chemotherapy) may kill more tumor cells. Giving NOV-002 together with
chemotherapy before surgery may make the tumor smaller and reduce the amount of normal tissue
that needs to be removed.
PURPOSE: This phase II trial is studying how well giving oxidized glutathione (NOV-002)
together with doxorubicin and cyclophosphamide followed by docetaxel works in treating women
with newly diagnosed stage II or stage III breast cancer.
Phase:
Phase 2
Details
Lead Sponsor:
University of Miami University of Miami Sylvester Comprehensive Cancer Center